Imperial College Healthcare NHS Trust — United Kingdom
Biochemistry, Genetics and Molecular Biology · Life Sciences
6h-index641citations10works0.02yr avg
Accepting Students?
No reports yet. Know if this professor is taking students?
Research Topics
Breast Cancer Treatment Studies(4), Global Cancer Incidence and Screening(4), Cancer Risks and Factors(3), HER2/EGFR in Cancer Research(2), Estrogen and related hormone effects(2)
Publications10 total
2016Open Access
Breast Cancer Research·2005· 82 citedOpen Access
Interpretation Single-agent gefitinib and gefitinib combined with anastrozole are well-tolerated and effective treatments for reducing the size of breast tumours and levels of ER phosphorylation when given as neoadjuvant therapy. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
2005
Impact of use of hormone replacement therapy on false positive recall in the National Health Services Breast Screening Programme: population-based prospective study
ANU Open Research (Australian National University)·2004
Journal of Hepatology·1995· 113 cited
Frequent Co-authors
Matthew Wallis(5), Emily Banks(4), Gillian Reeves(4), Valerie Beral(4), Diana Bull(4), Barbara Crossley(4), Moya Simmonds(4), Elizabeth Hilton(4), S. P. Bailey(4), Peter Briers(4), Ruth English(4), Alan Jackson(4), Elizabeth Kutt(4), Janet Lavelle(4), Linda Rockall(4), Mary Wilson(4), Julietta Patnick(4), Sami Shousha(3), Andreas Polychronis(2), H D Sinnett(2)